Celltrion Dodges Omalizumab Preliminary Injunction In Fledgling UPC Decision
UPC Concluded That Celltrion’s Actions Did Not Constitute Infringement
The Unified Patent Court is beginning to see its first actions involving pharmaceutical patents. In a case brought before the court that sought to put a leash on Celltrion’s EU-approved biosimilar to Novartis/Genentech’s Xolair (omalizumab), the court sided with the Korean firm.
